Adicet Bio, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Adicet Bio, Inc. (ACET) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.04 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.04M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.01M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.29M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.85M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $3.04M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $3.01M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $2.29M 10-K · filed 2025-03-06 | |
| 2022-12-31 | $1.85M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $1.73M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $1.75M 10-K · filed 2022-03-15 | |
| 2019-12-31 | $509.00K 10-K · filed 2021-03-12 | $53.00K 10-K · filed 2020-03-12 |
| 2018-12-31 | $274.00K 10-K · filed 2021-03-12 | $51.00K 10-K · filed 2019-03-18 |
| 2017-12-31 | $16.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |